Computational models and AI technology allow to dramatically accelerate the development of new drugs and medical devices, to reduce, refine and replace tests on animals and clinical trials, to improve the safety of medical products and significantly cut R&D costs.
Who talks about us
Who talks about us
Modeling & Simulation combined with artificial intelligence is the most effective way to innovate the R&D process in healthcare. Already successfully used for decades in many industrial sectors, this cutting-edge technology is finally about to revolutionize the medical industry. A computational approach can increase the safety of drugs and medical devices, while significantly reducing their development cost and the time to market.
Accelerate the development of new drugs and medical devices
Significantly cut R&D costs
Improve the safety of medical products
Reduce, refine and replace tests on animals and clinical trials
Days faster than traditional approach
Cost reduction
The Pursuit of Excellence in New Drug Development
We have built a unique cloud platform where powerful computational models, developed by top scientists at renowned universities, research centers and companies worldwide, are made available to the healthcare industry in an easy-to-use and cost-effective manner. Our game-changing approach to Modeling & Simulation means faster and way less expensive R&D for safer drugs and medical devices.
Upload specific data and set parameters
Run the simulation and get your outcomes
Download your report compliant with regulatory requirements
Our technology
We provide a series of cloud-based digital solutions that integrate computational models, so our clients do not need to worry about developing their own solutions and paying for very expensive software, IT infrastructures, and specialized personnel. The cloud guarantees total data security and the possibility to access the platform from everywhere in the world.
CBINSIGHTS recognized us as a major player in the Digital Twin & Biosimulations sector
We are part of Plug and Play’s Basel Accelerator Program